2 results
10-K/A
2023 FY
ELYM
Eliem Therapeutics Inc
29 Apr 24
Annual report (amended)
4:02pm
Exhibit Index
Incorporated by Reference | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Exhibit Number | Description of Exhibit | Form | File No. | Exhibit | Filing Date | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
3.1 | Amended and Restated Certificate of Incorporation of the Registrant. | 8-K | 001-40708 | 3.1 | August 12, 2021 | 3.2 | Amended and Restated Bylaws of the Registrant. | S-1 | 333-257980 | 3.4 | August 2, 2021 | 4.1 | Form of common stock certificate of the Registrant. | S-1 | 333-257980 | 4.1 | August 2, 2021 | 4.3 | Description of Securities | 10-K | 001-40708 | 4.3 | March 7, 2022 | 10.1 | Amended and Restated Investor Rights Agreement, dated May 21, 2021, by and among the Registrant and the investors listed on Schedule A thereto. | S-1 | 333-257980 | 10.1 | July 16, 2021 | 10.2+ | 2021 Equity Incentive Plan. | S-1 | 333-257980 | 10.4 | August 2, 2021 | 10.3+ | Forms of Option Agreement, Stock Option Grant Notice and Notice of Exercise under the 2021 Equity Incentive Plan. | S-1 | 333-257980 | 10.5 | August 2, 2021 | 10.4+ | Forms of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement under the 2021 Equity Incentive Plan. | S-1 | 333-257980 | 10.6 | August 2, 2021 | 10.5+ | 2021 Employee Stock Purchase Plan. | S-1 | 333-257980 | 10.7 | August 2, 2021 | 10.6+ | Form of Indemnification Agreement, by and between the Registrant and each of its directors and executive officers. | S-1 | 333-257980 | 10.8 | August 2, 2021 | 10.7+ | Executive Employment Agreement by and between the Registrant and Robert Azelby, effective October 1, 2020, as amended. | S-1 | 333-257980 | 10.9 | August 2, 2021 | 10.8+ | Executive Employment Agreement by and between the Registrant and Erin M. Lavelle, effective October 1, 2020, as amended. | S-1 | 333-257980 | 10.10 | August 2, 2021 | 10.9+ | Executive Employment Agreement by and between Eliem Therapeutics (UK) Ltd. and Valerie Morisset, Ph.D., effective January 1, 2021. | S-1 | 333-257980 | 10.11 | July 16, 2021 | 10.10+ | Separation and Consulting Agreement, dated February 13, 2023, by and between Eliem Therapeutics, Inc. and Robert Azelby. | 8-K | 001-40708 | 10.1 | February 13, 2023 | 10.11+ | Separation and Consulting Agreement, dated February 13, 2023, by and between Eliem Therapeutics, Inc. and Erin Lavelle. | 8-K | 001-40708 | 10.2 | February 13, 2023 | 10.12+ | Retention Agreement, dated February 14, 2023, by and between Eliem Therapeutics, Inc. and Valerie Morisset. | 10-K | 001-40708 | 10.12 | March 6, 2023 | 21.1 | List of subsidiaries. | S-1 | 333-257980 | 21.1 | August 2, 2021 | 23.1 | Consent of Independent Registered Public Accounting Firm. | 10-K | 001-40708 | 23.1 | March 28, 2024 | 23.1 |
10-K/A
2023 FY
ELYM
Eliem Therapeutics Inc
29 Apr 24
Annual report (amended)
4:02pm
The following table summarizes information about our equity compensation plans as of December 31, 2023. All outstanding awards relate to our common stock.
Plan Category | (a) Number of securities to be issued upon exercise of outstanding options and rights | (b) Weighted- average exercise price of outstanding options | Number of securities remaining available for issuance under equity compensation plans (excluding securities reflected in column (a)) | |||||||||||||
Equity compensation plans approved by security holders: | 2019 Equity Incentive Plan | 1,389,620 | $ | 3.70 | — | |||||||||||
2021 Equity Incentive Plan(1) | 3,276,190 | $ | 6.14 | 2,057,888 | ||||||||||||
2021 Employee Stock Purchase Plan(1) | — | N/A | 787,231 | |||||||||||||
Equity compensation plans not approved by security holders: | — | N/A | — | |||||||||||||
Total | 4,665,810 | N/A | 2,845,119 |
- Prev
- 1
- Next